The course of complicated Crohn's disease during therapy with Russian biosimilars of infliximab and adalimumab

AIM: to assess the course of complicated forms of CD against the background of therapy with Russian biosimilars of infliximab and adalimumab, as well as the survival rate of therapy in this group.

PATIENTS AND METHODS: a retrospective evaluation of patients with complicated CD who received infliximab or adalimumab with follow up at the institution for at least three consecutive years was performed. A total of 15 patients with complicated CD received infliximab therapy and 14 received adalimumab. The main clinical and demographic parameters and the rate of of intra-abdominal complications during 3 years of follow up of patients were analyzed.

RESULTS: in the infliximab group, a decrease in the rate of stenosis was noted during 3 years of follow up (from 12/15 (80%) to 3/6 (50%)), the rate of detection of other complications did not change, in addition, during the specified period, resection was performed in all patients in this subgroup. The median survival of therapy in this group was 11 (8.5; 24) months. In the adalimumab group, all 6 patients followed up showed resolution of stenosis at the beginning of the third year of therapy, while over the course of two years, the frequency of their detection remained the same as before the start of treatment. By the end of the 1st year of therapy, complete resolution of paraintestinal infiltrates was noted. During three years of observation, only 1 patient underwent resection, the median survival of therapy was 20.5 (14–24) months.

CONCLUSION: the study obviously has a number of limitations typical for a retrospective analysis of small samples. However, there is a decrease in the incidence of complications with infliximab or adalimumab therapy. There is a need for a well-designed prospective study on the dynamics of intra-abdominal complications in patients with CD against the background of GEBD.

1. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn”s disease. Gastroenterology. 2002;122:512–30.

2. Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: East meets West. Journal of Gastroenterology and Hepatology. 2020;35:380–389.

3. Belousova E.A., Shelygin Y.A., Achkasov S.I., et al. Clinical and demographic characteristics and therapeutic approaches in patients with inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the Russian Federation. The first results of the analysis of the National Register. Koloproktologia. 2023;22(1):65–82. (In Russ.). doi: 10.33878/2073-7556-2023-22-1-65-82

4. Knyazev O.V., Belousova E.A., Abdulganieva D.I., et al. The real practice of drug therapy of moderate and severe forms of inflammatory bowel diseases in Russia, the Republic of Belarus and the Republic of Kazakhstan. Interim results of the INTENT study. The Almanac of Clinical Medicine.2021;49(7):443–454. (In Russ.). doi: 10.18786/2072-0505-2021-49-061

5. Fan Y, Zhang L, Omidakhsh N, et al. Progression of Crohn's Disease in Newly Diagnosed Patients: Results from an Observational Study Using US Claims Data. Dig Dis Sci. 2024 Nov;69(11):4167–4177. doi: 10.1007/s10620-024-08591-7

6. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002 Jul;8(4):244–50. doi: 10.1097/00054725-200207000-00002

7. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010 Oct;139(4):1147–55. doi: 10.1053/j.gastro.2010.06.070

8. Cullen G, Vaughn B, Ahmed A, et al. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis. 2012 Apr;18(4):691–6. doi: 10.1002/ibd.21783